phase clinic plasma cellular pharmacolog studi gemcitabin novel deoxycytidin analog gemcitabin dfdc phase clinic pharmacolog trial minut weekli time week week maximum-toler dose mtd dose-limit toxic myelosuppress thrombocytopenia anemia import granulocytopenia nonhematolog toxic minim respons patient adenocarcinoma colon lung maximum dfdc plasma concentr minut infus proport total dose elimin due deamin rapid termin half-lif minut dose independ deamin product dfdu biphas kinet long termin phase hour sole metabolit urin concentr dfdc mononuclear cell proport dfdc dose infus increment dfdc dfdctp dose plasma dfdc concentr mumol/l satur dfdc accumul recommend dose phase II clinic trial solid tumor 